
Dr Catherine Carmichael, Victoria Cancer Agency Mid-Career Research Fellowship (Biomedical)
- Research Group Head, Leukaemia Modelling and Therapeutic Discovery
- Adjunct Senior Research Fellow, Monash University
- catherine.carmichael@hudson.org.au
- Role: Research Group HeadGroup: Leukaemia Modelling and Therapeutic Discovery
“Acute Myeloid Leukaemia (AML) is a blood cancer that develops rapidly with low survival rates and limited treatment options. My research aims to identify leukaemia-specific weaknesses that can be therapeutically targetable, with the ultimate goal of improving survival rates for patients diagnosed with AML.” Dr Catherine Carmichael
Dr Catherine Carmichael is a molecular cancer biologist whose research is focused on identifying the key mechanisms driving Acute Myeloid Leukaemia (AML) progression and developing novel therapeutic approaches to treat this devastating blood cancer.
Dr Carmichael’s specialist areas are the molecular and biological processes underpinning both normal and malignant blood cell development, and using sophisticated cellular and animal modelling approaches to identify therapeutically targetable molecular and biological dependencies of leukaemia cells.
She has made significant contributions to the understanding of the underlying molecular alterations that drive both inherited and acquired forms of myeloid and erythroid leukaemia.
Dr Carmichael has received more than $3 million in grant and fellowship funding from both National and State government agencies (NHMRC and Victorian Cancer Agency), as well as from philanthropic funding bodies such as the Leukaemia Foundation of Australia.
Education
2004-2008 | PhD | University of Melbourne/WEHI | Melbourne |
2002 | Bachelor of Science (Hons) | University of Melbourne/WEHI | Melbourne |
1999-2001 | Bachelor of Biomedical Science | University of Melbourne | Melbourne |
Awards and Fellowships
2023-2026 | Mid-Career Fellowship | Victorian Cancer Agency |
2020-2024 | Ideas Grant | NHMRC |
2018-2020 | Project Grant | NHMRC |
2018 | Senior Postdoctoral Fellowship | Monash University |
2013 | Grant-In-Aid | Leukaemia Foundation of Australia |
2008-2010 | Postdoctoral Fellowship | Leukaemia Foundation of Australia |
2004-2007 | Dora Lush PhD Scholarship | NHMRC |
Affiliations
Adjunct Senior Research Fellow | Monash University |
Links
Google scholar ORCID Scopus Twitter LinkedIn
Selected publications
Carmichael CL, Wang J, Nguyen T, Kolawole O, Benyoucef A, De Mazière C, Milne AR, Samuel S, Gillinder K, Hediyeh-Zadeh S, Vo ANQ, Huang Y, Knezevic K, McInnes WRL, Shields BJ, Mitchell H, Ritchie ME, Lammens T, Lintermans B, Van Vlierberghe P, Wong NC, Haigh K, Thoms JAI, Toulmin E, Curtis DJ, Oxley EP, Dickins RA, Beck D, Perkins A, McCormack MP, Davis MJ, Berx G, Zuber J, Pimanda JE, Kile BT, Goossens S, Haigh JJ (2020) The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1. Blood 136:957-973.
Fagnan A, Bagger FO, Piqué-Borràs MR, Ignacimouttou C, Caulier A, Lopez CK, Robert E, Uzan B, Gelsi-Boyer V, Aid Z, Thirant C, Moll U, Tauchmann S, Kurtovic-Kozaric A, Maciejewski J, Dierks C, Spinelli O, Salmoiraghi S, Pabst T, Shimoda K, Deleuze V, Lapillonne H, Sweeney C, De Mas V, Leite B, Kadri Z, Malinge S, de Botton S, Micol JB, Kile B, Carmichael CL, Iacobucci I, Mullighan CG, Carroll M, Valent P, Bernard OA, Delabesse E, Vyas P, Birnbaum D, Anguita E, Garçon L, Soler E, Schwaller J, Mercher T (2020) Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. Blood 136:698-714.
Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, Carmichael CL, Masih KE, Morris SM, Lindsley RC, Janke LJ, Alexander TB, Song G, Qu C, Li Y, Payne-Turner D, Tomizawa D, Kiyokawa N, Valentine M, Valentine V, Basso G, Locatelli F, Enemark EJ, Kham SKY, Yeoh AEJ, Ma X, Zhou X, Sioson E, Rusch M, Ries RE, Stieglitz E, Hunger SP, Wei AH, To LB, Lewis ID, D’Andrea RJ, Kile BT, Brown AL, Scott HS, Hahn CN, Marlton P, Pei D, Cheng C, Loh ML, Ebert BL, Meshinchi S, Haferlach T, Mullighan CG (2019) Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nat Genet 51:694-704.
Thirant C, Ignacimouttou C, Lopez CK, Diop M, Le Mouël L, Thiollier C, Siret A, Dessen P, Aid Z, Rivière J, Rameau P, Lefebvre C, Khaled M, Leverger G, Ballerini P, Petit A, Raslova H, Carmichael CL, Kile BT, Soler E, Crispino JD, Wichmann C, Pflumio F, Schwaller J, Vainchenker W, Lobry C, Droin N, Bernard OA, Malinge S, Mercher T (2017) ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell 31:452-465.
Tang JZ, Carmichael CL, Shi W, Metcalf D, Ng AP, Hyland CD, Jenkins NA, Copeland NG, Howell VM, Zhao ZJ, Smyth GK, Kile BT, Alexander WS (2013) Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. Proc Natl Acad Sci U S A 110:6091-6096.
Carmichael CL, Metcalf D, Henley KJ, Kruse EA, Di Rago L, Mifsud S, Alexander WS, Kile BT (2012) Hematopoietic overexpression of the transcription factor Erg induces lymphoid and erythro-megakaryocytic leukemia. Proc Natl Acad Sci U S A 109:15437-15442.
Hahn CN, Chong CE*, Carmichael CL*, Wilkins EJ, Brautigan PJ, Li XC, Babic M, Lin M, Carmagnac A, Lee YK, Kok CH, Gagliardi L, Friend KL, Ekert PG, Butcher CM, Brown AL, Lewis ID, To LB, Timms AE, Storek J, Moore S, Altree M, Escher R, Bardy PG, Suthers GK, D’Andrea RJ, Horwitz MS, Scott HS (2011) Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 43:1012-1017. *Equal contribution.
Ng AP, Hyland CD, Metcalf D, Carmichael CL, Loughran SJ, Di Rago L, Kile BT, Alexander WS (2010) Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome. Blood 115:3966-3969.
Carmichael CL, Majewski IJ, Alexander WS, Metcalf D, Hilton DJ, Hewitt CA, Scott HS (2009) Hematopoietic defects in the Ts1Cje mouse model of Down syndrome. Blood 113:1929-1937.